Trends
Hair Longevity Is a Framework—Not Yet a Proven Product Category
A European expert consensus can organize research questions, but it is not product-outcome evidence or proof of a global market trend.
The archive
Every story, filterable by evidence.
123 stories · page 9 of 11
Trends
Post-GLP-1 Aesthetics: A Survey Signal, Not a Proven Market Shift
A survey-led trend signal on post-weight-loss skin concerns, separated from clinical evidence for skin change and from claims that any aesthetic treatment is effective.
Aesthetics
GLP-1 Medicines and Hair Loss: What the Association Signal Shows
Large reviews and current labeling support an association signal, but they do not prove one direct mechanism for every case or justify stopping treatment without a prescriber.
Aesthetics
At-Home LED Masks: Where the Evidence Is Strongest—and Where Marketing Runs Ahead
At-home LED evidence is indication-, device- and protocol-specific: selected acne studies do not validate every rejuvenation claim.
Science
A 0.002% Peptide Outperformed 0.002% Retinol in One Company-Authored Trial
A precise comparison of cyclized hexapeptide-9 and a very low-dose retinol comparator—without turning one 56-day company-authored study into a class-wide verdict.
Aesthetics
Injectable Exosomes: Why the Safety Conversation Is Different
Topical and injectable exosome claims should never be treated as the same evidence category.
Science
Vegan PDRN: Innovation Claim or Naming Shortcut?
Why plant- or biotech-derived nucleotide materials need analytical equivalence and product-specific human evidence before inheriting clinical PDRN claims.
Archive
The Peptide Boom: Separate Oral Evidence From Topical Claims
The randomized evidence is encouraging but route-, formula- and endpoint-specific; oral collagen-derived findings cannot validate every topical peptide serum.
Science
Topical Exosomes for Skin Rejuvenation: Promising, but Not Standardized
A new 2026 scoping review finds encouraging signals for topical exosomes but major heterogeneity and standardization gaps.
Science
PDRN Is Everywhere. The Human Evidence Is Smaller Than the Hype
Seven randomized trials with 183 participants span different products, routes and indications; injectable findings cannot be transferred to retail topicals.
Skin
What 2026 Beauty Results Really Say: L’Oréal, Estée Lauder and Shiseido Compared
Three primary company disclosures point to very different kinds of beauty momentum in 2026. LCY compares the periods, metrics and category signals without turning unlike numbers into a false ranking.
Skin
‘Mask-Level’ Toner Claims: What Shiseido’s New Elixir Launch Can—and Cannot—Establish
Shiseido’s 21 August 2026 announcement of a new Elixir high-moisture lotion is a useful product-intelligence signal, but it is not independent proof of superior skin outcomes. LifeCareYou separates what the company has documented about the launch from what still needs finished-product, comparative and post-market evidence. The timely signal is the claim language: the release defines “mask-level” as moisturizing performance equivalent to an Elixir sheet mask, then separately states a...